XML 57 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Mar. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue $ 44,319 $ 29,806 $ 80,480 $ 90,633    
Constrained for Future Recognition [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue 3,300   1,200      
Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue 23,889 $ 23,256 48,049 $ 42,137    
China [Member] | Product Revenue, Net [Member]            
Contract with Customer, Liability [Abstract]            
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration 4,700   4,700      
AstraZeneca Agreements [Member]            
Contract with Customer, Liability [Abstract]            
Deferred Revenue 178,219   178,219   $ 175,646  
AstraZeneca Agreements [Member] | China [Member]            
Contract with Customer, Liability [Abstract]            
Deferred Revenue 24,800   24,800      
Beijing Falikang Pharmaceutical Co Ltd | Product Revenue, Net [Member]            
Contract with Customer, Liability [Abstract]            
Reductions to gross accounts receivable $ 2,500   $ 2,500     $ 500